CervoMed reports early 12‑week NfL decline in Phase 2a nfvPPA trial
CervoMed Inc. presented initial results from the open‑label portion of its Phase 2a study of neflamapimod in patients with nonfluent variant primary progressive aphasia. Over the first 12 weeks, mean plasma neurofilament light chain fell by about 3.1 pg/mL, with a larger 5.7 pg/mL drop in the subgroup that started with above‑median levels. The drug was generally well tolerated, with one participant stopping due to transient liver‑enzyme elevation. The company said it will share 24‑week biomarker findings in November and expects topline clinical data in the first quarter of 2027.
Why it matters
The early biomarker decline suggests the drug may affect neuronal damage in a disease with no approved therapies, which could drive investor interest pending later efficacy data. The company’s timeline indicates that additional data will become available in November 2026 and Q1 2027, potentially influencing the stock price when released.
Key facts
- 1The Phase 2a trial enrolled 25 participants with nfvPPA. stocktitan.net
- 2Mean baseline plasma NfL was 45.7 pg/mL (SD 39.6 pg/mL). stocktitan.net
- 3Mean plasma NfL decreased by approximately 3.1 pg/mL over the first 12 weeks. stocktitan.net
- 4In participants with baseline NfL at or above the median (13 patients), the mean decline was about 5.7 pg/mL. stocktitan.net
- 5Glial fibrillary acidic protein levels remained stable during the 12‑week period. stocktitan.net
- 6One patient discontinued because of elevated liver enzymes, which resolved after stopping the drug. stocktitan.net
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.